From trials to practice: Immune checkpoint inhibitor therapy for melanoma patients in Norway

Denise Reis Costa, Anna K. Winge-Main, Anna Skog, Kaitlyn M Tsuruda, Trude Eid Robsahm, Bettina Kulle Andreassen · 2024

Read From trials to practice: Immune checkpoint inhibitor therapy for melanoma patients in Norway by Denise Reis Costa, Anna K. Winge-Main, Anna Skog, Kaitlyn M Tsuruda, Trude Eid Robsahm, Bettina Kulle Andreassen (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11681278.txt.

Description

Denise Reis Costa and five co-authors published this study in 2024. It describes how immune checkpoint drugs were used for skin melanoma across Norway after the drugs entered care between 2014 and 2017. Norway has some of the highest melanoma rates in the world, so the stakes are high.

Using national registries, the team tracked 2,083 adults who got these drugs through 2021. Nearly half started on one drug, nivolumab, for disease that had spread. Real-world patients were older than trial patients and more often had cancer in the brain. About one in five would have been barred from the trials because of other immune diseases. The authors note that this gap raises fair questions about how well trial results carry over to everyday patients.

Catalog record

CREATORDenise Reis Costa, Anna K. Winge-Main, Anna Skog, Kaitlyn M Tsuruda, Trude Eid Robsahm, Bettina Kulle Andreassen
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE30 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11681278

Browse the full library · About the Tower of Babel